The US Food & Drug Administration’s somewhat tumultuous time in the spotlight of the COVID-19 response effort likely means a broader public appreciation for the “immense complexity” of the agency’s responsibilities, former Commissioner Andy von Eschenbach suggested during the Food & Drug Law Institute annual meeting on 18 May.
“I think the public has a much better appreciation of the challenges that the agency has to respond to,” von...






